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Abstract
Background: This qualitative sub-study aimed to explore the experiences of participants on the National Cancer
Research Institute ZICE clinical trial, a randomised trial assessing two types of bisphosphonate treatment in breast
cancer patients with bone metastases. Participants in the clinical trial were randomly allocated to receive either
zoledronate, delivered by an intravenous (IV) infusion at clinic, or oral ibandronate, taken at home.
Methods: Qualitative research interviews were conducted with participant groups organised by treatment and
location. Interviews covered experiences and understanding of bisphosphonate treatment, the experience of the
delivery mechanisms (IV or oral), side effects and benefits, and quality of life issues. The analytic framework was
interpretative phenomenological analysis.
Results: This paper reports on one of four superordinate themes: participants’ experience of the ZICE trial, which
explores the participants’ experiences with clinical trial-related processes. Results show that participants were
generally satisfied with their randomised treatment, although most participants had an initial preference for oral
bisphosphonates. Some difficulties were reported from participants for both interventions: needle phobia, poor
veins, difficulty with swallowing and gastric side effects, but pain control was improved with both modes of
delivery. However, the infused bisphosphonate was reported to lose effectiveness after three weeks for some
participants, whereas the oral bisphosphonate was reported to give consistent pain control. Geographical location
and distance to travel made little difference to convenience of access to clinic as the reported lengths of travel
time were similar due to traffic congestion in the urban areas. Most participants understood the trial processes,
such as randomisation, and information about bisphosphonates but some participants showed little understanding
of certain aspects of the trial. Some participants reported difficulties in accessing dental treatment due to their
dentist’s perceptions of bisphosphonate treatment.
Conclusions: In trials of medicinal products, especially when testing for non-inferiority, participants’ preferences
and idiosyncrasies in relation to treatments should not be assumed. This study has shown that in a trial context,
participants’ views can usefully add to the main trial outcomes and they should be taken into account when
prescribing in the real world.
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Background
The QUALZICE study is a multicentre, qualitative sub-
study that explores the experiences of participants in the
National Cancer Research Institute (NCRI) randomised
phase III ZICE trial, summarised in italics below:
The ZICE trial is a randomised trial, sponsored by
Velindre NHS Trust, assessing two types of
bisphosphonate treatments in breast cancer
participants with bone metastases. Participants are
randomly allocated to receive either zoledronate,
delivered by an intravenous (IV) infusion at clinic, or
oral ibandronate, which is taken at home. Zoledronate
is considered, in many centres, to be the standard
bisphosphonate of choice, given as an IV infusion over
15 minutes every 3–4 weeks. Oral ibandronate could
potentially have significant advantages over IV
zoledronate as the tablet is small, taken once daily at
home and without the side effects or inconveniences of
an IV infusion. However, a large scale direct
comparison between IV zoledronate and oral
ibandronate has not been carried out and ZICE aims
to address this with the enrolment of 1400 participants
as a non-inferiority trial using a primary endpoint of
skeletal related events. The trial was coordinated by
the Wales Cancer Trials Unit and developed on behalf
of the NCRI Breast Cancer Clinical Studies Groupa.
When comparing these two treatments within the clin-
ical trial, in addition to looking at the outcomes of the trial
(that is, treatment efficacy, safety, health economics and
quality of life), it is important to consider the experiences
of participants receiving either drug and how they under-
stand the procedures associated with the trial.
Quantitative data from the clinical trial will provide in-
formation about safety and efficacy aspects, as well as an
analysis of quality of life and the cost of treatments, using
questionnaires. These quantitative comparisons will be
used to determine the treatment that should become rou-
tine treatment for patients. This qualitative study adds an
in-depth, participant-led exploration of individual experi-
ence of the treatments and participation in the clinical
trial, which cannot be collected using questionnaires.
Qualitative methodologies are commonly used to explore
the understanding and experiences of patients and health
professionals in health and illness research and are well
established in mixed-method evaluations of complex public
health or service interventions, which increasingly incorp-
orate process evaluations as an integral part of randomised
control trial designs [1-3]. Historically, although the import-
ance of patient experience is recognized to an extent in
clinical investigational medicinal product (IMP) trials, ef-
forts to capture such impacts have been restricted to
quality-of-life tools and other quantitative scales.
Qualitative approaches provide an opportunity to gen-
erate more detailed and in-depth insights into patient
experiences than cannot be captured by standardized
tools [4]. As such, the role of qualitative research in
clinical trials is also growing. For example, there are a
number of empirical examples that demonstrate how
qualitative research can improve the design and running
of clinical trials [5,6].
Reporting on the results of the QUALZICE study, this
paper demonstrates that patient experiences can be ex-
plored in depth, and that embedded qualitative methods
can be used in clinical trials alongside quantitative mea-
sures of participant outcomes to generate insights that are
of interest for ethical as well as more practical reasons,
and that could inform future trial design and implementa-
tion. At the request of the chief investigator and the ZICE
Trial Management Group (TMG), this paper is written in
a style intended to be accessible to a broad audience and
is designed to engage with triallists and clinicians.
The aims of the QUALZICE study were to understand
the experiences of people taking part in a clinical trial of
a supportive care intervention and to explore the differ-
ent experiences between taking a supportive care inter-
vention by IV infusion or orally.
Methods
The QUALZICE study was developed on behalf of the
ZICE TMG (which includes clinicians, methodologists
and patient representatives). It was funded by Velindre
NHS Trust’s small grants committee and was coordi-
nated by the Wales Cancer Trials Unit (WCTU). The
study was supported by Cancer Research UK and Marie
Curie core-funded staff at WCTU. The protocol received
the favourable opinion of the Cambridgeshire 4 Research
Ethics Committee.
Recruitment
Participants were recruited from three locations in England
and Wales, which vary in their urban or rural characteris-
tics, to give a range of participant experiences. A key differ-
ence between the administration of oral versus IV therapy
is the need for the participant to attend the centre where
the IV infusion is delivered. It was therefore thought that
ease of access to the medical centre would affect the patient
experience and so participants were purposively selected
from the three sites.
Sites were selected purposively and pragmatically if
they were a ZICE recruiting site, were able to demon-
strate a spread of urban and rural characteristics and
were local to a suitably skilled researcher.
Sampling of participants was purposive, aiming to engage
homogeneous groups in exploring recurring themes. The
participants were categorised according to the treatment re-
ceived (IV infusion or tablet) and also by type of location
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(semi-urban, rural or urban). Therefore, overall from the
three centres, there were six groups.
We aimed to recruit six to ten participants to each
group in line with the usual recommendations for sample
sizes when applying interpretative phenomenological ana-
lysis (IPA) methodology. The justification for this sample
size per group is well supported in the methodological lit-
erature with the intention of depth, rather than breadth of
analysis [7]. From the 6 groups, a total of 42 patients were
interviewed. Data collection ceased when a representative
sample had been recruited to each group. IPA method-
ology is highly descriptive and not reliant on saturation of
data, neither is it intended to be generalisable across popu-
lations [7]. The numbers of participants in each group are
given in Table 1.
Participants meeting the following criteria were in-
cluded in the study:
1. ZICE clinical trial participants (breast cancer
participants with newly diagnosed bone metastases)
2. had been receiving their allocated ZICE protocol for
a minimum of 12 weeks
3. were able and willing to give informed consent to
participate in the study and to discuss issues relating
to their diagnosis, treatment and quality of life issues
4. were able to understand questions and speak English
to the extent needed to participate in the interview
Participants were not included in the study if there
was any factor that affected communication or compre-
hension. Eligible participants from the ZICE trial were
approached by the research nurses at the recruiting site,
where they were given study information to see whether
they would like to enter QUALZICE. At their next visit,
if they agreed, their contact details were passed to the
researcher to arrange an appointment. Written consent
was taken at the time of the interview by the researcher.
Data collection
Individual semi-structured interviews were undertaken
with participants at a time and location of their choice.
The interviews were up to 52 minutes in duration, and
the mean interview time was 22 minutes. All but two of
participants chose to be interviewed at home.
The study team developed a master interview schedule
with questions and prompts; however, the interviews
evolved over time with the interview content developing
in line with the interviewees’ answers. A second version
was produced after the first few interviews and was used
for the remainder of the study. Smith and Osborn [8]
highlight the importance of interview schedules being
used to guide rather than dictate the interview, enabling
participants to discuss issues pertinent to them. The inter-
view schedule was therefore used to ensure that the inter-
views gathered the required information for the trial,
while allowing participants the space to speak about wider
concerns. Interview questions are outlined below.
Version 1:
a) Which treatment are you on?
b) What is your understanding of why you are taking
this treatment?
c) Take us through what happened at your last visit to
clinic?
d) What do you have to do at home for your treatment?
e) How has the treatment affected your daily life?
f ) Do you have any new symptoms since taking the
treatment?
g) Does your treatment affect your family/social life?
h) Is there anything you’d like to talk about in relation
to your treatment?
Version 2:
a) How did you hear about the trial?
a. Which treatment are you on?
b) Is this the treatment that you preferred?
b. b. …and with hindsight?
c) How long have you been on your treatment?
d) How did you feel after your first treatment?
e) What is your understanding of why you are taking
this treatment?
f ) Take us through what happened at your last visit
to clinic?
g) How long does it does it take you to get to clinic?
h) What do you have to do at home for your treatment?
i) How has the treatment affected your daily life?
g) How is your quality of life since starting the trial?
k) Have you been referred to talk to anyone about
your condition?
l) Do you have any new symptoms since taking the
treatment?
m)Does your treatment affect your family/social life?
n) Do you have pain? Has this been helped by the
bisphosphonates?
o) Is there anything you’d like to talk about in relation
to your treatment?
Sample size estimates in qualitative research interviews
are more art than science and depend on the quality of
Table 1 The number of participants, where they lived and
their trial arm
Semi-urban Rural Urban Total
Infusion 6 9 6 21
Oral 3 8 10 21
Total 9 17 16 42
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the data collected. For this study, data collection ceased at
the discretion of each researcher, which coincided with
our target group sizes. As experienced researchers and in-
terviewers, we were also mindful of inappropriate imposi-
tions on this patient population.
The researchers digitally recorded the interviews and
wrote field notes, where appropriate (with the partici-
pant’s permission), to record incidents occurring during
the interview, non-verbal communication or reactions at
the time of the interview. The interviews were tran-
scribed in full, and verbatim and anonymised transcripts
were coded using NVivo 8 software. Standard operating
procedures for data protection ensured participant de-
tails were secure at all times.
Data analysis
The analytic framework for this qualitative sub-study is
based on IPA [7,9]. This approach is increasingly used to
address health-care and quality of life research topics,
where the aim is to understand the meaning that events
or states have for participants based on their subjective
accounts [10]. It is also interpretative in the sense that
the researchers’ conceptions and experience, as brought
to the analysis, are also recognized in a ‘two-stage inter-
pretation process, or double hermeneutic’ [10].
IPA is based on an idiographic approach beginning with
a single case as a basis for developing more general cate-
gories in a detailed case-by-case analysis. The transcripts
from the three sites were systematically analysed in several
stages [8] as follows:
 Preliminary reading: The first transcript is read line
by line and annotated with initial comments.
 Early analysis: Initial comments are grouped into themes.
 High-level abstraction: Connections between themes
are developed until an organised master list and
thematic account of the case is achieved.
 Subsequent transcripts: New themes are tested
against the previous transcripts as non-recurring
themes are tested against following transcripts.
Connections across cases are noted to identify a set
of superordinate themes for the group.
Reflexivity and validity
Three interviewers were selected for their experience in
the psychosocial issues of advanced cancer participants.
All three interviewers (AN, DF and JM) have extensive
clinical and academic experience of advanced cancer. DF
and JM have made significant contributions to breast
cancer research and teaching, and all three are familiar
with a range of qualitative methodologies. In terms of
interpretation, this level of experience adds understand-
ing and depth to the analysis since the researchers were
well aware of the illness trajectory and context of care,
and these were the basis for further questions to individ-
ual participants. The interviewers clearly defined them-
selves as researchers and the interview time as a non-
clinical event; however, patients were given information
about how to access extra support if necessary at the
end of the session. The data was analysed by a post-
doctoral researcher supervised by AN and the results
were discussed by the interview team at several meetings
during the course of the study.
Four superordinate themes emerged from the QUALZICE
study interview data:
1. Participants’ experience of the ZICE trial – to be
presented here
2. Health-care professionals - the relationship between
participants and clinical trial research nurses and
doctors
3. Individual experience of illness – including the
experience of being ill, self-image, hope and coping,
and significant others
4. Interviewer’s actions - The data indicate that the
three interviewers, who were involved in data
collection, had somewhat different interviewing
styles and ways of building rapport with the study
participants. The literature on methodological
issues related to interviewing cancer patients about
their illness and treatment is currently somewhat
scarce and thus an in-depth analysis of this data
will lead to a potentially valuable methodologically
oriented publication.
The purpose of this paper is to describe the experi-
ences of people taking part in this trial and to describe
differences between the two methods of treatment deliv-
ery. Therefore data from the first superordinate theme,
which directly relates to the ZICE trial, will be reported
here. Data captured within the remaining themes will be
presented elsewhere.
Results
Participants’ experience of the ZICE trial
This theme captures participants’ experiences of the
clinical trial and relates to topics concerning treatment
and location as per the study aims, but also trial pro-
cesses and procedures, and the impact of the trial assess-
ments and treatment side effects. Figure 1 displays the
theme and its associated subthemes.
Theme 1: Patient perceptions of trial issues
Generally, participants who were interviewed in the
QUALZICE study had a clear understanding of the ran-
domisation process of the ZICE trial, which allocated them
to either IV zoledronate at a clinic or oral ibandronate at
Nelson et al. Trials 2013, 14:325 Page 4 of 13
http://www.trialsjournal.com/content/14/1/325
home. They realized that neither they nor their doctor were
able to choose the treatment they would receive:
I didn’t have a choice, obviously the computer chose
which, which one I was gonna go on, so I didn’t actually
have a choice. (SU07, semi-urban area, IV treatment)
However, there were cases where the participant was
clearly interested in receiving the oral treatment and the
trial was therefore perceived as a chance of getting that
treatment. These quotations seem to indicate that some
participants thought that they were on the trial only if
they were receiving oral treatment:
He [the doctor] said, ‘I don’t know whether I can get you
on it,’ at that stage he had no idea, anyway, to cut a long
story short, he did get me on the trial and that’s how it
all came about. (R07, rural area, oral treatment)
We decided that rather than go ahead with the
intra…, intravenous drip, we would try and get on the,
on the trial, and fortunately, I did. (U06, urban area,
oral treatment)
Decision to join the trial
Participants reported three main reasons for joining the
ZICE trial: the possibility of receiving the oral treatment,
being constantly monitored and helping others. Some par-
ticipants felt that participating in the trial, on either arm,
would give them more security, as they were coming to
the clinic more regularly and could therefore receive add-
itional attention from the health-care professionals:
For me it means that there’s always somebody checking
up on me more, so I feel a bit more secure. (R11, rural
area, IV treatment)
Altruism was the third frequently mentioned reason for
deciding to join the ZICE trial. Some participants felt that
as they were supposed to receive the bisphosphonate
treatment anyway, then being able to help others while
doing so was an additional benefit. In some cases the phil-
anthropic reasons were intertwined with a feeling of per-
sonal gain:
I’m quite pleased to be in the trial and it works both
ways, helping other people, but uh, it also means that
Figure 1 Participants’ experiences theme.
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I’m monitored on a regular basis, so, that, I don’t have
a problem with that at all. (R03, rural area, IV
treatment)
Preferences about treatment
Preferences for oral treatment Despite having a clear
understanding of the randomisation process, the major-
ity of interviewed participants had a clear preference
about the treatment they were hoping to receive after
randomisation. Most of those participants who had a
clear initial preference were hoping to be randomised to
the oral treatment. One of the reasons for wanting the
oral treatment was the inconvenience of clinic visits:
’Cos we live so far away from here [the local cancer
centre], I didn’t want to be, extra trips, coming up just
to have a, an injection or, we’ve tried to tie it in with
other treatment and it just seemed a bit, you know,
lots of organisation. If you could take, take tablets?
Yes, it’d be easier, just to take that at, that at home, so
[laughs] all for that. [laughs] (R14, rural area, oral
treatment, 61 minutes travel to hospital)
Some of those participants who preferred to receive
the oral treatment considered the difficulties with intra-
venous treatments and discomfort with needles and
blood that they had experienced previously, as the main
reason for wanting tablets:
Participant: It [oral treatment] was the one I wanted,
without a doubt.
Interviewer: Why was that then?
Participant: Just because my veins are so bad and I
have a bit of a phobia with needles as well. (U04,
urban area, oral treatment)
In addition to these practical reasons, some parti-
cipants perceived the oral treatment as more normal
and more effective. Because the oral treatment meant
a reduced number of clinic visits, some participants
saw it as creating fewer interruptions to their ordinary
daily routine, thus allowing them to continue with
their lives as normal. Others felt that if they did not
have to go to the clinic they could almost forget about
their illness and carry on with their lives, without be-
ing constantly reminded of their condition. For some
participants the oral treatment felt more effective due
to its continuous nature:
I thought tablet would be, would be sort of more
normal you can say, having it on a daily basis and
less, sort of, dramatic, you know? (U02, urban area,
oral treatment)
Well I thought logical sense, that if you actually had
the steady drip of a drug that, into you every day, that
it’s got to be more effective than having a big blast of it
once a month and then it petering out towards the end
of the month. (R09, rural area, oral treatment)
Preferences for IV treatment Although the preference
for the oral treatment was expressed by more than half
of all participants, a minority were hoping to receive the
intravenous treatment, whilst a greater number were un-
sure or had no preference. Some participants had previ-
ously experienced difficulties with swallowing tablets;
others were feeling sick as a side effect of their other
treatments, thus making the oral treatment somewhat
problematic:
Somehow or other I preferred the infusion, you know, I
thought to myself, ‘I prefer the infusion to the tablets,’ you
know,’cos I imagine the tablets to be enormous and I’m
not very good at swallowing, so, um, yes, I was quite
happy with the infusion. (R08, rural area, IV treatment)
Interestingly, many of those participants who preferred to
receive the intravenous treatment referred to this as being a
safer option. Because the intravenous treatment meant
more clinic visits, the participants felt that they were better
monitored and could receive additional attention from
health-care professionals. Another reason for perceiving the
intravenous treatment as a safer option was the reality of
receiving it in the clinic, thus the treatment could not be
missed or forgotten (although as a specific interview ques-
tion, very few participants stated that they had missed oral
doses). Receiving the intravenous treatment in the hospital
environment and it being administered by medical profes-
sionals made it also seem more ‘real’ than tablets, which
would have been taken alone at home:
I suppose, you don’t like being at the hospital, but
actually, maybe they are sort of keeping a slightly
closer eye on what’s happening if you’re in the system
more frequently. That’s how I felt I think at the time. I
don’t feel like that at the moment, but that’s how I
think I felt at the time. [laughing] So maybe that was
the plus side of it. (U16, urban area, IV treatment)
No preference In addition to those participants who had
a clear preference about treatment, there were also those
who claimed not to have had particular preferences. This
indifferent or passive attitude was linked to faith in the
care they were receiving and the fact that neither of the
treatments created additional interruptions to their daily
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routines. Some participants also felt that they should be
grateful for receiving a treatment at all, rather than com-
plain about the possible inconveniences it might create:
To be honest with you, if they had said the tablet, I
had thought well, as long as uh, you know they’re
giving me this, and I don’t care what I have, so long as
I’m getting it. (U15, urban area, IV treatment)
Preferences and randomisation In the context of clin-
ical trials, where participants are randomised to different
treatment arms without taking their preferences into
consideration, it is interesting to explore the reactions of
those individuals who ended up receiving the treatment
they did not wish to receive. Among the individuals who
were interviewed in the QUALZICE study, there were
nine participants who were not randomised to the treat-
ment arm they initially preferred. Eight of those partici-
pants wanted to receive the oral treatment, but were
randomised to the intravenous treatment.
Interestingly, among those nine individuals who were
receiving the treatment they initially did not want to re-
ceive, there were only two who were disappointed with
the treatment they were receiving. One of those partici-
pants, a woman who had received the intravenous treat-
ment for almost three years, but wanted to receive the
oral treatment, had asked to swap several times, but her
request had always been refused:
I hoped and prayed I wasn’t going to have the infusion,
[laughs] and of course I ended up with the infusion. Um,
only because it’s painful and um, I thought tablets were
a damn sight easier, but it came up with the infusion
and that’s it, you know, you’ve got to accept it haven’t
you. (R01, rural area, IV treatment)
The other participant who was disappointed was re-
ceiving the oral treatment. She had previously felt sick
as a side effect from another treatment and thought that
from that perspective the intravenous treatment would
have been better for her:
I would say probably I would have the injection if I
thought that I was going to keep being sick and all of
that,’cos that did worry me because I just think I, I don’t
want to be missing out on this tablet’s not in my system.
So perhaps the, perhaps the injection might have been
better for me. (SU05, semi-urban area, oral treatment)
The remaining seven individuals, who all had wanted
the oral treatment but had been randomised to the
intravenous treatment, were generally satisfied with their
treatment. For some of them the initial preference for
the oral treatment was linked to practical problems, such
as discomfort related to intravenous treatments or the
inconvenience of clinic visits, but once a solution to
these issues was found, they were generally pleased:
Um, probably the tablets, only because they had trouble
with my veins, but that’s sorted now because I’m on the
PICC [peripherally inserted central catheter] line so it’s
no problem. (U16, urban area, IV treatment)
Inconvenience of tablet procedure Most participants
who were on the oral treatment found the tablet proced-
ure fitted well into their everyday routine and did not
cause any significant inconvenience or interruptions:
This treatment that – no, no, it’s just, just like taking
tablet, no, easy, you know. (R14, rural area, oral
treatment)
The fact that participants could not eat or drink any-
thing for at least six hours before taking the tablet did
create some discomfort. For example, participants found
this aspect of the tablet-taking procedure was difficult to
follow in situations where they woke up with a head-
ache. It was also difficult for those who could not sleep
well and were used to having a drink during their sleep-
less hours. It is interesting to see how trivial but habitual
aspects of participants’ everyday lives, like having a cup
of tea in bed before getting up, suddenly acquired sig-
nificance and are missed:
The difficulties I suppose, if you can call them
difficulties, um, is, say for example, I don’t sleep very
well. Um, so, whereas perhaps I’d have got up, maybe
had a cup of tea, read a magazine, gone back to bed.
Ah, four hours later, five hours later, whatever – or two
or three in some cases - um, got back up again, I can’t
do that. But, ok, that’s, I can live with that. Um, the
other thing, for example if, say you wake up in the
morning and you’ve got a headache. And you can’t do
anything about that until you’ve taken, until you’ve
taken your tablet. … It’s about 30, 40 minutes before you
can do anything really, after the tablet. Or certainly
that’s my understanding. … Um, so, I wouldn’t call
them, really, disadvantages, for me, that far outweigh
the minuses. (U06, urban area, oral treatment)
The data also indicate that some participants had misin-
terpreted the information given in the participant informa-
tion leaflets, interpreting some aspects more strictly than
needed and remembering other aspects slightly differently.
For example, one participant seemed to have interpreted
the information about the need to stay in an upright pos-
ition after taking the tablet as a need to stand up. At the
same time she remembered that this ‘standing-up period’
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had to last for half an hour, though the participant informa-
tion leaflet suggested staying upright for one hour. Another
participant seemed to have understood that she had to re-
frain from eating or drinking for exactly six hours before
taking the tablet:
Well I hope I’m doing it right. Take it after, I’m just
trying to think, six hours or something with no food,
um, and you have to then be standing up so I call, call
it my standing up pill, so um, so I have it first thing
when I get out of bed in the morning and that’s the
trouble you see when I have to stay standing up, so I
have to work then. (R09, rural area, oral treatment)
This extract illustrates the importance of information-
giving but also checking understanding to ensure that
participants are not subjected to undue inconvenience.
Theme 2: Treatment processes
Procedure at clinic
The clinic procedure for participants on the ZICE trial
seemed to follow a similar pattern in all three study
sites. While participants were satisfied with the general
procedure at clinic, they were dissatisfied with the ex-
tended waiting times in clinic:
I go upstairs straight away and take my card. Ahhh I
go, then get called to give some bloods, and then um, I
go back into the waiting room and it’s about on a good
day it’s about uh 20 minutes to half, but we get there,
I have my blood taken, see the consultant, then I have
to wile away two hours. The only complaint I’ve got is
getting my treatment. There’s, the prescription is never
ready so I always have to wait for the nurse to go to
get the prescription because either the doctor doesn’t
send it down or pharmacy are haven’t done it and
they have to wait to get it checked. Quite often we’re
there for a good two hours whereas my treatment only
takes half an hour. (U03, urban area, IV treatment)
Trial processes
The issue of informed consent about randomisation was
discussed earlier together with participants’ decision to
join the trial and their preferences for treatment. This
section discusses participants’ understanding of their
treatment, understanding of possible side effects and
knowledge of the ZICE trial and procedures.
Participants’ understanding of the treatment was on
most occasions correct. Most of the interviewed partici-
pants were aware that they were receiving bisphosphonate
treatment to strengthen their bones:
Well, I believe it strengthens bones, it uh puts, it was
explained to me that it almost puts like cling film
coating round the bones and protects it, I don’t, I don’t
know if it stops it spreading, um I take Arimidex for the
breast cancer, um to stop that spreading and um, do you
know. I don’t know. (R01, rural area, IV treatment)
However, while most of the participants were clear
about the bone-strengthening effect of bisphosphonates,
some participants were not clear:
Interviewer: What, what’s your understanding of why
you’re taking the tablet?
Participant: Not very much, quite frankly. I, I, I just
feel that, uh, it’s a, a, obviously it’s a new drug fighting
cancer. An’, and my particular type of cancer, the, uh,
breast cancer of the bone. (R07, rural area, oral
treatment)
Most participants had an accurate understanding of
the trial and its objectives. Participants understood that
the trial aimed to compare the effectiveness of intraven-
ous and oral bisphosphonate treatment:
It’s er for the longer-term benefit of other people and
obviously what proves to be the best treatment you know
whether it’s this form or the tablet form erm that’s my
understanding. (SU08, semi-urban area, IV treatment)
Nevertheless, there were cases where participants had
misinterpreted the information about the trial and its
procedure. The aspect of the trial procedure that seemed
to be most confusing seemed to be the length of the trial
(see also below ‘End of trial’):
But I thought there were three parts to it? Wasn’t
there a sort of long infusion, a tablet or a short
infusion? I can’t remember, I think, what I understood
was, the standard practice was an infusion that took
longer than 15 minutes. That’s what I vaguely
remember, that was what was, had been given in the
past. (SU01, semi-urban area, IV treatment)
I’m not quite sure. Is it uh nine months, no? (U13,
urban area, IV treatment)
The issue of experiencing side effects was discussed
in every interview and the findings related to this are
reported below. Additionally, participants’ understand-
ing and awareness about the possible side effects were
discussed. The data reveal that participants’ views
about side effects and how well they should be made
aware of the possible side effects differed. Some partic-
ipants felt that they wanted to be more informed and
kept constantly aware of the possible side effects,
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whereas other preferred not to read the participant in-
formation leaflets:
Every so often they should remind you actually, what
the side effects are, what could be the side effects, you
know. Because you go on it, you’ve got your bit of
paper, um, you then, as I say if you get the tablet
option, I have completely forgotten until you
mentioned it. [laugh] Um, and then you get so caught
up in pain, caught up in the spread of the cancer, that
you kind of forget this other bit, and possibly the side
effects of it. (SU01, semi-urban area, IV treatment)
To be honest, I tend not to read the side effects,
because it ca—, I, it can, sort of, as you say, you know,
it can frighten you a bit, can’t it? You, you got
something that’s supposed to cure something that
causes all these other things and you’re: ‘Oooh, I don’t
wanna know.’ (U06, urban area, oral treatment)
End of trial As mentioned above, participants seemed to
be relatively unaware of the length of the trial, although
this was clearly stated on the participant information
sheet. Patients were followed up for 96 weeks, or nearly 2
years. Follow-up data was collected for a further three
years but the patient did not have to attend for assess-
ments. Perhaps, given the length of the trial it is not sur-
prising that patients had forgotten some initial details.
Similarly, patients seemed not to have a very clear under-
standing of what is going to happen at the end of the trial:
Interviewer: Do you know how long you’ll be on the trial
for? What’s your understanding of how long you’ll…
Participant: Well I haven’t really been told for how long
it is, I’m just assuming it’s for as long as I need it, I ju—,
just don’t know. (U16, urban area, IV treatment)
The participants who had come to the end of the trial
had decided to continue with the trial drug indefinitely
(as per trial protocol). Their doctors’ suggestion to con-
tinue seemed to be the main reason for their decision:
Oh no, he just said that, um, that I’d come to the end
of the trial and that I could take the drug if I wanted
to take the drug, which I thought, well, what options
are there, there’s no other options. (U09, urban area,
oral treatment)
The data thus indicate that participants’ ability to take
in new information is limited and depends largely on
their current interests and problems. While the informa-
tion about the end of trial is important in the context of
informed consent, clearly the processes related to the
end of trial are not important for participants at the mo-
ment of joining the trial, and thus this information may
not in reality play an important role in their decision-
making. Reminding participants about certain trial pro-
cedures later in the course of trial, including the process
of coming to the end of the trial, may be helpful.
Theme 3: Side effects
Before giving an overview of the research findings related
to side effects, it is worth reiterating that the aim of this
study was not to collect data about the frequency of
experiencing different side effects. Instead, the aim was to
explore the experiences of participants receiving bis-
phosphonate treatment in two different forms – oral or
intravenous. Hence, in the following we will discuss some
of the side effects in relation to what it meant for the par-
ticipants to have different side effects, in particular where
this varied between the different forms, rather than a more
detailed exploration of the frequency of side effects.
Polypharmacy
The participants who were interviewed in the QUALZICE
study were typically receiving other treatments in addition
to the bisphosphonate treatment. Herceptin and Arimidex
were the most frequently mentioned other drugs received
on prescription. Because of taking many different tablets
or receiving several different intravenous treatments, the
participants had difficulties with attributing certain side ef-
fects, which were collected via questionnaires in the main
ZICE trial, to a specific treatment. Despite the inter-
viewers’ efforts to understand whether the emergence of
side effects coincided with the start of the bisphosphonate
treatment, the participants in many cases still struggled to
determine what part of their treatment was causing their
side effects:
Tiredness. Fatigue. Nausea. And, um, you do
something and you just can’t go. Or you do it and
that’s your day ended…. It’s very difficult to say
really’cos I’ve got pituitary problems and adrenalin
problems … and I’m on, ah, steroid, which gives off the
same things. So you’ve got two tablets doing similar
things. And you’re not sure which one’s doing it. (U09,
urban area, oral treatment)
Gastric side effects
As the data below indicate, participants on the ZICE
trial reported gastric side effects, such as diarrhoea, indi-
gestion, reflux and nausea. The sample size means that
these results are descriptive rather than attributable to
either trial arm and are presented in the context of par-
ticipants’ daily lives.
In addition to creating general discomfort and pain,
these symptoms also created interruptions to participants’
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everyday activities, even if they were not experienced regu-
larly or frequently. The participants who had experienced
these symptoms once were more wary about their possible
reoccurrence and thus avoided doing certain things that
they used to enjoy doing (for example, going for a walk
with a friend or eating certain food). These participants
were also keener on staying at home to be able to deal
with the symptoms in a convenient manner and avoid the
symptoms occurring in a public place:
I’ve had a touch of reflux, … I would, I would say it
would be because of starting those tablets. I can’t, I
don’t think it was to do with anything else that I can
remember. (R06, rural area, oral treatment)
The collected data reveal interesting differences in par-
ticipants’ perceptions about the ways of dealing with
gastric side effects. As the data below indicate, doctors
prescribe stomach protectors, such as omeprazole, to
participants who are experiencing gastric side effects.
However, participants’ perception of whether stomach
protectors can be used to ease the gastric side effects
varies, with some participants not using the medicine as
they believe that bisphosphonate tablets have to be taken
on an empty stomach:
I do get a bit, some nausea after taking it. And, um, if,
if, if I leave it, I usually leave it an hour before I have
breakfast an’, and it’s all clearer.
Well really that’s not, I take omeprazole. That, that
isn’t really a help, because you’ve got to take the
ibandronate on an empty stomach. … In, it can’t, it
can’t take that, it, at least, well a minimum of half an
hour after. (U12, urban area, oral treatment)
Flu-like symptoms
Some of the participants who were receiving intravenous
treatment reported having flu-like symptoms. These
symptoms seemed to have occurred only after the first
couple of treatments:
Only on that initial one it felt very flu like and sort of
achy erm but now I’ve got used to it so apart from
obviously erm feeling a bit tired erm you know I don’t
have any problems at all. (SU08, semi-urban area,
IV treatment)
Dental problems
In addition to generally checking for the understanding
of possible side effects, some interviews focused speci-
fically on the question about the possible dental side
effects (osteonecrosis of the jaw). Interestingly, the
bisphosphonate treatment did not create real dental
problems for participants’, but it sometimes made it dif-
ficult for some of them to get the dental treatment that
they needed:
Like I had a problem couple of weeks ago – one of my
crowns came off and they couldn’t fit it back. He did
try but it came off again. He said, I can’t do it. He
said normally, I take the tooth out, but I knew that if I
had the tooth out I’d come off the um trial so in the
end, he just left it there, he said he’d ground it down
and he said I’ll just leave the root in. Now I wasn’t
quite sure about that but I went yesterday and [the
research nurse] was saying, oh yes that’s fine. She was
quite happy with it if the dentist was so. (U14, urban
area, oral treatment)
Pain
Talking about pain was one of the recurring themes in
the QUALZICE study. In this section, those parts of the
participants’ interviews that referred to the pain they
were experiencing in the present moment, that is, during
the QUALZICE study, is discussed.
Reduced pain The participants reported that the pain
they experienced before starting their current treat-
ment was on many occasions unbearable and debi-
litating, but that their pain levels had decreased
significantly since starting their treatment. Because
most participants were receiving different treatments
simultaneously, it was difficult to determine which one
was the most effective for pain control. Some partici-
pants attributed the decrease or absence of pain to the
bisphosphonate treatment they were receiving. How-
ever, it was more common for participants to attribute
the decrease in pain levels to the radiotherapy they had
received, or to think that the combination of radiother-
apy and bisphosphonate treatment was keeping their
pain under control:
Interviewer: So when you did take the bisphosphonates
that helped?
Participant: Yes completely. No pain since. (U04,
urban area, oral treatment)
Interviewer: So you wouldn’t say there’d been any
change in pain, you haven’t had much pain before the
treatment, that changed once you started the trial?
Participant: No, no,’cause I, I,’cos I had obviously
[words incomprehensible] pain in the left foot and they
zapped it with radiotherapy and that’s been so much
better. I don’t really get a lot of pain at all. (R10, rural
area, oral treatment)
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Wearing-off effect of IV treatment As already men-
tioned, not all participants attributed the decrease in their
pain levels to the bisphosphonate treatment. Neverthe-
less, several participants who were receiving intraven-
ous treatment reported that they could feel their pain
levels increase in the final week of their four-weekly
bisphosphonate treatment. Because the participants
were experiencing this wearing-off effect, it appears that
some doctors had changed their treatment from four-
weekly to three-weekly. However, this was not done for
all participants who reported feeling more pain in the
fourth week of their treatment cycle:
Once I’ve had my um treatment I’m fantastic, you
know, for like two, oh it’s brilliant, … But then the
third week, like now this week, it’s this I’m waiting for
next week to go, I start to ache – my body is kind of
like trying to tell me I’m ready for it. … But once I
have had it, within a day or so, I’m like a little button.
(U01, urban area, IV treatment)
Tiredness
Some participants complained about feeling tired and
without energy. For some participants who mentioned this
tiredness seemed to be related to the intravenous treat-
ment; they felt tired the next day after getting the infusion.
For others, tiredness seemed to be a general symptom,
not specifically linked with the bisphosphonate treatment.
The transitory fatigue associated with the bisphosphonate
treatment seemed almost normal and was mentioned in
passing. When it was perceived to be a more ongoing
symptom then it was explained in a lengthier manner:
Yeah, I think I felt tired. Um, but on the whole I didn’t
feel any, any sort of serious effects. … But looking at
the note, I mean the original thing I had about it, it
seems to be one of the side effects anyway, doesn’t it?
(R03, rural area, IV treatment)
I do feel tired after it. (U05, urban area, IV treatment)
Discussion
Participants’ reasons for joining the trial were largely phil-
anthropic, as reported elsewhere [11], but they also repor-
ted joining for the chance of receiving oral medications (as
IV was the standard treatment available outside the trial)
and to receive additional attention from health-care profes-
sionals, which resonates with earlier work by Sulmasy et al.
[12], who found that a primary motivation for trial partici-
pants was for enhanced treatment, with some leanings to-
wards therapeutic misconceptions [13,14].
Participants were, on the whole, satisfied with the trial
and their place within the trial process. There was, how-
ever, an underlying element in that participants seem to
have interpreted that they were only in the trial by virtue
of the treatment allocated to them. Hence, they thought
they were getting a new treatment that was on trial, which
they couldn’t otherwise have. This attitude has implica-
tions in relation to trial equipoise and both patients’ and
medical teams’ understanding of the concept in the con-
text of a clinical trial. Most participants who had a clear
initial preference were hoping to be randomised to the
oral treatment; this preference was expressed due to the
inconvenience of clinic visits or difficulties with intraven-
ous treatments and discomfort with needles and blood.
Several participants reported needle phobia. Many partici-
pants reported that the insertion of needle into their veins
had become increasingly difficult, as could be expected for
this participant group. Certain chemotherapy drugs have a
vesicant effect and may cause long-term damage. Repeated
venepuncture is also associated with scarring and sclerosis
in cancer patients, whose skin may already be delicate.
Participant experience of this issue will further inform the
main trial outcomes and the analysis of trial attrition rates
due to this reason. This is a lengthy trial for those partici-
pants who may become venous compromised, and it raises
questions concerning the management of this issue.
Nevertheless, the findings show that most participants
dealt with the intravenous drug administration well and
that, once practical difficulties were overcome, there were
advantages with this route.
On the other hand, although the oral route had been
the route of choice for many, there were disadvantages
as well as advantages. The taking of daily medication
was a reminder of the cancer and the restrictions im-
posed on eating caused disruption to some people’s lives.
The findings also point to the complex issue of provid-
ing and seeking information on treatment options. On
the one hand patients need to be, and may want to be,
thoroughly informed about the options available to them
[15,16]; on the other hand they may choose to ignore
the information provided or make sense of it in ways
that contradict or disregard the medical experts’ advice
[17,18]. Thus, there are challenges for those who provide
care for cancer patients, for they have to find a balance
between participants’ need to make sense of their own
situation and also correctly and sufficiently informing
them of the reality of their condition.
Despite rigorously developed trial information documents
and research nurse support, participants frequently ap-
peared uninformed about procedures, for example, the rea-
son for blood tests, end of trial procedures and the oral
treatment protocol. It appears that participants’ ability to
take in new information is limited and depends largely on
their current interests and problems. While the informa-
tion about the end of trial is important in the context of
informed consent, clearly the processes related to the end
of trial are not important for participants at the moment
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of joining the trial, and thus this information may not in
reality play an important role in their decision-making.
Reminding participants about certain trial procedures later
in the course of a trial, including the process of coming to
the end of the trial, may thus be necessary. Furthermore,
given some participants’ misunderstandings about the oral
protocol and end of trial arrangements, the importance of
information-giving and also checking understanding to
ensure that participants are not subjected to undue incon-
venience is highlighted. This emphasises the need for re-
search nurses to ensure participant understanding is
evident at all stages of the trial process.
The bisphosphonate treatment did not create signifi-
cant dental problems for participants, although several
reported extra visits to their dentist with one participant
attending appointments every six weeks. The fact that
participants were on bisphosphonate treatment did
make it difficult for some of them to get the dental
treatment that they needed. Some dentists were report-
edly wary of participants receiving treatment and re-
ferred them elsewhere.
Strengths and limitations
The key strength of this paper is that it reports on pa-
tient experiences of the treatment arms, as an outcome
measure for the main ZICE trial, based on interviews
with patients currently participating in an ongoing clin-
ical trial of an investigative medicinal product. Qualita-
tive studies are extremely rare in this context.
The sample comprises six homogeneous groups. This
is a large sample for an IPA study but as with any quali-
tative study, the results are not generalisable nor do they
make any theoretical contributions to the social science
literature. Instead they complement the main trial find-
ings and the reported outcomes for the patient group re-
ceiving these treatments.
Conclusions
Geographical characteristics relating to the differences
between urban and rural areas were not an issue for par-
ticipants due to the trade-off between distance and the
time taken to travel through heavy traffic.
Participants frequently referred to the oral treatment
in terms of its acceptability as more normal and more
effective. They also mentioned that this format was more
‘continuous’ in controlling symptoms. For those partici-
pants randomised to receive oral treatments on the
ZICE trial, the fasting and upright protocol was well tol-
erated by most but misunderstood by several, who were
reluctant to use their prescribed stomach protector medi-
cines before taking the tablet. One participant referred to
it as her ‘standing-up tablet’, as she thought she needed to
be on her feet for the protocol. Most participants missed
their early morning cup of tea. Several participants on the
intravenous arm complained of a wearing-off effect.
The main practical reason for preferring the intraven-
ous treatment was participants’ previously experienced
difficulty with taking tablets. Participants reported that
the pain they experienced before starting their trial treat-
ment was on many occasions unbearable and debilitat-
ing, but that their pain levels decreased significantly
following the start of the trial treatment.
In summary, the recommendations, for consolidation
in future studies of this type, from this study include:
 Qualitative interviews are well received by clinical
trial participants. This approach is more efficient
and less costly if embedded in the full trial design.
 Consider the practical difficulties faced by people
undergoing intravenous infusions and offer suitable
alternatives, for example a PICC, injection at their
community health clinic rather than going to the
hospital or even that the district nurse comes to
their home.
 Check participant comprehension of trial
interventions and processes at multiple time points
throughout the trial.
 Provide participant education and ensure
understanding of pain control and opiate use.
 Consider a participant-held information card in the
context of dental care.
The main ZICE trial aimed to assess the non-inferiority
of either medication. However, participants’ views regard-
ing the differing modes of delivery should not be assumed.
This study has shown that in a trial context, participants’
views can usefully add to the main trial outcomes, espe-
cially in a trial of non-inferiority. The ZICE trial has
reported that ibandronate failed to satisfy non-inferiority
criteria in terms of the skeletal-related event rate in bone-
metastatic breast cancer compared with zoledronic acid,
and this should be considered along with patients’ views
when prescribing in the real world.
End note
aMain ZICE trial ref numbers: Eudract No: (2005-
001710-40).
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